Skip to main content
Flatiron Health

Flatiron Health

Flatiron Health’s mission is to improve and extend lives by learning from the experience of every person with cancer.www.flatiron.com

Search complete. 20 mentions across 18 episodes found for "Flatiron Health".

Nov 16, 2026

Steve KrausHOST
1:33
Before CMS, he actually himself was a founder, led a company called Anomaly, which is a venture-backed startup using AI to streamline healthcare payments.
Steve KrausHOST
1:42
Before that, he was at Flatiron Health, one of the leading healthcare venture success stories, and then Google, not a small company itself.
Steve KrausHOST
1:49
So, Jacob, thanks for joining the Heart of Healthcare.
Steve KrausHOST
1:52
It's great to be here.
Eric SinghiGUEST
9:41
I was really excited to be able to present this at WCLC.
Eric SinghiGUEST
9:44
What Adora told us, what the eight-year update told us was, you know, what can three years of ulcerative mortonib do? What can it accomplish in a clinical trial setting? But we wanted to figure out from a practical standpoint, are patients actually staying on therapy for those three years in the real world? And so what we did was we used the Flatiron Health database, US-centric, of course, right, to look at just over 800 patients with resected EGFR mutant non-small cell lung cancer who were treated with adjuvant osomertinib.
Eric SinghiGUEST
10:09
And we found some pretty striking results.
Eric SinghiGUEST
10:11
So at year one, approximately 75% of patients were still on adjuvant osomertinib.
Sagar LonialGUEST
2:49
So we know that despite progress, real-world practice patterns demonstrate ongoing challenges in relapsed and refractory myeloma.
Sagar LonialGUEST
2:57
And data from the PREAMBL and CONNECT-MM study, as well as the Flatiron Health retrospective analysis, suggests that these are major challenges, the four that we just talked about, in terms of managing real-world patients with relapsed and refractory myeloma.
Sagar LonialGUEST
3:14
And while we certainly have great therapeutic options, and we're gonna talk about those in just a moment, many of them are not necessarily accessible to every patient for a number of different reasons.
Sagar LonialGUEST
3:25
And so clearly, new therapeutic options to help provide treatments that can be easily administered in a number of different settings are clearly indicated and, in fact, were recognized by the FDA as a potential unmet medical need.
Sagar LonialHOST
2:49
So we know that despite progress, real-world practice patterns demonstrate ongoing challenges in relapsed and refractory myeloma.
Sagar LonialHOST
2:57
And data from the PREAMBL and CONNECT-MM study, as well as the Flatiron Health retrospective analysis, suggests that these are major challenges, the four that we just talked about, in terms of managing real-world patients with relapsed and refractory myeloma.
Sagar LonialHOST
3:14
And while we certainly have great therapeutic options, and we're going to talk about those in just a moment, many of them are not necessarily accessible to every patient for a number of different reasons.
Sagar LonialHOST
3:25
And so clearly, new therapeutic options to help provide treatments that can be easily administered in a number of different settings are clearly indicated and, in fact, were recognized by the FDA as a potential unmet medical need.
Sagar LonialGUEST
2:49
So we know that despite progress, real-world practice patterns demonstrate ongoing challenges in relapsed and refractory myeloma.
Sagar LonialGUEST
2:57
And data from the PREAMBL and CONNECT-MM study, as well as the Flatiron Health retrospective analysis, suggests that these are major challenges, the four that we just talked about, in terms of managing real-world patients with relapsed and refractory myeloma.
Sagar LonialGUEST
3:14
And while we certainly have great therapeutic options, and we're gonna talk about those in just a moment, many of them are not necessarily accessible to every patient for a number of different reasons.
Sagar LonialGUEST
3:25
And so clearly, new therapeutic options to help provide treatments that can be easily administered in a number of different settings are clearly indicated and, in fact, were recognized by the FDA as a potential unmet medical need.
Sagar LonialHOST
2:49
So we know that despite progress, real-world practice patterns demonstrate ongoing challenges in relapsed and refractory myeloma.
Sagar LonialHOST
2:57
And data from the PREAMBL and CONNECT-MM study, as well as the Flatiron Health retrospective analysis, suggests that these are major challenges, the four that we just talked about, in terms of managing real-world patients with relapsed and refractory myeloma.
Sagar LonialHOST
3:14
And while we certainly have great therapeutic options, and we're going to talk about those in just a moment, many of them are not necessarily accessible to every patient for a number of different reasons.
Sagar LonialHOST
3:25
And so clearly, new therapeutic options to help provide treatments that can be easily administered in a number of different settings are clearly indicated and, in fact, were recognized by the FDA as a potential unmet medical need.
Jason RowleyNARRATOR
3:11
which uses AI to analyze biological and medical data to better understand chronic diseases and identify potential treatments.
Jason RowleyNARRATOR
3:20
Before spending two years as a principal at SignalFire, Rauf led business development at clinical trial recruitment startup Iterative Health and previously oversaw partnerships at Flatiron Health, an oncology data company acquired by Roche, for $1.9 billion back in 2018.
Jason RowleyNARRATOR
3:39
Rauf said, if you're building a company that's selling into the life sciences, one of the hardest things to do is starting that initial commercial flywheel.
Jason RowleyNARRATOR
3:49
His sales chops, deep understanding of the healthcare ecosystem, and extensive industry relationships gave Limited Partners, the investors in VC Funds, the confidence that he could spot strong startups and help them land customers.
Jason RowleyNARRATOR
4:04
Proximal's backers include VC firms SignalFire and Kleiner Perkins, Bertelsmann Healthcare Investments, and individual investors such as Dimension Capital co-founders Nan Li and Zivane Darr.
Jason RowleyNARRATOR
4:18
Anne Abernathy, co-founder of Highlander Health and former principal deputy commissioner of the FDA, is also an investor.
Jason RowleyNARRATOR
4:25
She first met Raouf when they worked together at Flatiron Health, where she served as chief medical officer.
Jason RowleyNARRATOR
4:32
She told TechCrunch that his ability to build relationships and spot industry bottlenecks made a lasting impression.
speaker_0NARRATOR
0:12
Welcome everyone to the Emoj AI in Business podcast.
speaker_0NARRATOR
0:15
Today's guest is Richard Kanaki, head of data science and AI at Flatiron Health.
speaker_0NARRATOR
0:20
Flatiron Health develops technology and data solutions that help oncology teams generate and apply real-world evidence to improve cancer care and research.
speaker_0NARRATOR
0:28
Its platform connects clinical expertise with structured data and AI-enabled insights to support treatment, regulatory, and scientific decision-making.
speaker_0NARRATOR
0:36
In this episode, Richard explains why AI agents in pharma are only as reliable as the data foundation and semantic layer beneath them.
Sagar LonialHOST
2:08
And what we see with the real-world patterns is that there remain ongoing challenges in relapsed and refractory myeloma.
Sagar LonialHOST
2:15
Data from the Preamble study, the ConnectMM study, and the Flatiron Health retrospective data analyses demonstrating that about 70% of patients developed triple-class refractory and yet continued to reuse prior drug classes.
Sagar LonialHOST
2:31
What this means is that many patients cycled through previous mechanisms without necessarily getting the benefit of new therapeutic approaches.
Sagar LonialHOST
2:39
And these are, in fact, the top four challenges for patients and myeloma docs in the community.
Sagar LonialHOST
2:08
And what we see with the real world patterns is that there remain ongoing challenges in relapsed and refractory myeloma.
Sagar LonialHOST
2:15
Data from the Preamble study, the ConnectMM study, and the Flatiron Health retrospective data analyses demonstrating that about 70% of patients developed triple-class refractory and yet continued to reuse prior drug classes.
Sagar LonialHOST
2:31
What this means is that many patients cycled through previous mechanisms without necessarily getting the benefit of new therapeutic approaches.
Sagar LonialHOST
2:39
And these are, in fact, the top four challenges for patients and myeloma docs in the community.

8 more episodes mention Flatiron Health.

Create an account to see the whole feed, search across every transcript, and follow the entities you care about.

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.